Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psidii Guava Extract for Mild and Symptomless COVID-19
NCT04810728Phase 3Completed
- Sponsor
- Faculty of Medicine, Baiturrahmah University
- Start
- Jun 2020
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Psidii in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Faculty of Medicine, Baiturrahmah University. Primary endpoint: Changes of inflammatory cells and marker at 7 days. Started Jun 2020; status: completed.
02
Drugs
Psidii
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04810728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04810728.